Skip to main content
ILLUMINA, INC. logo

ILLUMINA, INC. — Investor Relations & Filings

Ticker · ILMN ISIN · US4523271090 LEI · SQ95QG8SR5Q56LSNF682 US Manufacturing
Open in API
Filings indexed 2,572 across all filing types
Latest filing 2020-11-19 Director's Dealing
Country US United States of America
Listing US ILMN

About ILLUMINA, INC.

https://www.illumina.com

Illumina, Inc. develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company is a provider of DNA sequencing and array-based technologies. Its portfolio includes next-generation sequencing (NGS) platforms, microarrays, library preparation kits, and bioinformatics software. These products and services are utilized by researchers and clinicians for applications in life science research, translational and consumer genomics, molecular diagnostics, oncology, and reproductive health. The company's solutions are designed to advance genomic discoveries and enable precision medicine by providing tools for DNA, RNA, and protein analysis.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2020-11-19 English
PRIMARY DOCUMENT
Director's Dealing
2020-11-19 English
PRIMARY DOCUMENT
Director's Dealing
2020-11-17 English
425 Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Illumina, Inc. The text describes an event related to the company's pending acquisition of GRAIL, including receipt of a second request from the FTC under the Hart-Scott-Rodino Act, and provides information about the transaction status and regulatory process. It also includes cautionary forward-looking statements and references to future filings such as a Form S-4 registration statement. The document is an announcement of a significant event (an update on a merger/acquisition process) rather than the merger proxy statement or registration statement itself. It does not contain financial statements or detailed financial analysis but rather regulatory and transaction update information. This fits the category of a Regulatory Filing (RNS), which is the fallback for miscellaneous SEC filings that do not fit other specific categories like M&A filings or proxy statements. The document is not a full merger filing (like DEFM14A or SC TO-*) but an 8-K current report providing an update on the transaction process and regulatory review.
2020-11-10 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Illumina, Inc. It reports an event related to the company's pending acquisition of GRAIL, specifically the receipt of a second request from the FTC under the Hart-Scott-Rodino Act, which is a regulatory review step in merger transactions. The document discusses the status of the acquisition, regulatory review, and future filings (Form S-4 registration statement) but does not contain financial statements or detailed financial analysis. It is an announcement of a material event related to a merger transaction but not the merger filing itself (such as a DEFM14A or SC TO-*). The document is not a full financial report, earnings release, or management discussion. It is a regulatory filing reporting a material event (other event) pursuant to SEC rules. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other categories.
2020-11-10 English
PRIMARY DOCUMENT
Director's Dealing
2020-11-09 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.